BPC
BBIO icon

Bryce Point Capital’s BridgeBio Pharma BBIO Stock Holding History

Bryce Point Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$609K Sell
11,717
-2,139
-15% -$104K 0.74% 37
2025
Q2 		$598K Buy
+13,856
New +$504K 0.51% 125

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bryce Point Capital's BBIO Position: Q3 2025 in Review

Bryce Point Capital reduced its BridgeBio Pharma (BBIO) stake by 15% in Q3 2025, selling an estimated $104K and leaving 11,717 shares worth $609K. The position accounts for 0.74% of the portfolio, ranked #37.

Bryce Point Capital first reported a position in BBIO in Q2 2025 and has held it in 2 quarters since. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

  • Bryce Point Capital held 11,717 shares of BridgeBio Pharma worth $609K as of Q3 2025.
  • Bryce Point Capital sold 2,139 BridgeBio Pharma shares in Q3 2025, an estimated $104K.
  • BridgeBio Pharma made up 0.74% of Bryce Point Capital's portfolio in Q3 2025, its #37 holding.
  • Bryce Point Capital first reported a position in BridgeBio Pharma in Q2 2025 and has held it in 2 quarters since.
  • 392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Bryce Point Capital's 13F filing for Q3 2025, filed 6 Nov 2025.